Home > Neurology > ECF 2020 > ECF Round-Up Articles > No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS

No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS

Presented By
Prof. Heinz Wiendl , University of Muenster, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECF 2020
Trial
Phase 3, ASCLEPIOS
Multiple sclerosis (MS) patients are at an increased risk of infections compared with the general population. A recent analysis of the phase 3 ASCLEPIOS I/ASCLEPIOS II trials showed no association between a decrease in serum immunoglobulin (Ig) levels and the incidence of infections in ofatumumab-treated patients with relapsing MS. Igs play a major role in immunoprotection. In MS patients receiving disease-modifying therapies, particularly B-cell-depleting therapies, serum IgM and IgG levels below the lower limit of normal (LLN) have been associated with an increased risk of infections. Igs have also been considered as a biomarker for assessment of infection risk in MS patients.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on